Lerociclib plus fulvestrant in patients with HR+/HER2− locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial
Tong Li(Second Affiliated Hospital of Xi'an Jiaotong University), Deyong Zhang(Hunan University), Changping Shan(Affiliated Hospital of Jining Medical University), Xinhong Wu(Hubei Cancer Hospital), Fuming Qiu(Second Affiliated Hospital of Zhejiang University), Changlu Hu(Anhui Provincial Hospital), Xinlan Liu(Yunnan Agricultural University), Xiaohua Zeng(Chongqing Cancer Hospital), Tao Sun(Liaoning Cancer Hospital & Institute), Yang Luo(Chongqing University of Posts and Telecommunications), Shusen Wang(Sun Yat-sen University), Xiaojia Wang(Wenzhou Medical University), Qingyuan Zhang(Jiangxi University of Traditional Chinese Medicine), Zhendong Chen(Anhui Medical University), Bing Zhao(Xinjiang Medical University), Hongyan Jia(Shanxi Medical University), Zhongsheng Tong(Tianjin Medical University Cancer Institute and Hospital), Xi Yan(Sichuan University), Yumin Yao(Liaocheng People's Hospital)
Cited by 10
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)
|Journal of Clinical Oncology|2021|350
Induction of Pyroptosis and Its Implications in Cancer Management
|Frontiers in Oncology|2019|274